View on Pubmed.gov 40162642 | View on doi.org 10.1056/NEJMoa2... | View the free full text Full text
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
- University of Texas Southwestern Medical Center, Dallas.
- Parkland Health System, Dallas.
- Clinic for Cardiology, Angiology, and Intensive Care Medicine, Rheinisch-Westfälische Technische Hochschule Aachen University, University Hospital Aachen, Aachen, Germany.
- Department of Medicine, Division of Cardiology, Dalhousie University, Halifax, NS, Canada.
- Institute of Cardiovascular Sciences, University College London, London.
- Section of Endocrinology, Yale University School of Medicine, New Haven, CT.
- Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland.
- Kuratorium für Heimdialyse Kidney Center, Munich, Germany.
- Friedrich Alexander University of Erlangen, Erlangen, Germany.
- Department of Biostatistics, University of Washington, Seattle.
- Imperial Clinical Trials Unit, Imperial College London, London.
- Novo Nordisk, Søborg, Denmark.
- Swansea University Medical School, Swansea, United Kingdom.
- University of North Carolina School of Medicine, Chapel Hill.
SOUL Study Group
- F Perez Manghi,
- J M Pozzi,
- A J Lorenzatti,
- V E Visco,
- D Piskorz,
- L Nardone,
- M I Chahin,
- M Bustamante Labarta,
- C Luquez,
- I J MacKinnon,
- T Pieber,
- R Prager,
- E Fließer-Görzer,
- C Ebenbichler,
- P Fasching,
- C Mathieu,
- C De Block,
- F Duyck,
- E Heyns,
- B Lapauw,
- C Vercammen,
- L A A Turatti,
- D R Franco,
- R R Rea,
- H R Kurtz Lisboa,
- J E Salles,
- J F K Saraiva,
- A G T Fonseca,
- M H Vidotti,
- S O Leite,
- N Aggarwal,
- H Bajaj,
- R Schlosser,
- L Noronha,
- S Pedersen,
- S Peterson,
- G Tellier,
- J Weisnagel,
- S Beca,
- H Alasaad,
- Z Punthakee,
- J G B Mancini,
- R Tytus,
- T P P Ransom,
- K Connelly,
- M Husain,
- M Tsoukas,
- L Ji,
- J Liu,
- G Yuan,
- X Ye,
- X Dong,
- F Bian,
- A A Angelo,
- R Sanchez Garcia,
- I D Hernandez Erazo,
- E A Hernández Ruiz,
- J E Gómez Mesa,
- S Canecki Varzic,
- J Vucak Loncar,
- V Simegi-Djekic,
- T Ticinovic Kurir,
- S Tusek,
- D Rahelic,
- S Marusic,
- I Kruljac,
- D Fabris Vitkovic,
- M Oznerova,
- J Vrkoc,
- B Doležalová,
- M Haluzik,
- Z Jankovec,
- J Olsovsky,
- J Zemanova,
- P Kyselova,
- A Smahelova,
- S Gregersen,
- A-M Z Olsen,
- D Mikkelsen,
- K Egstrup,
- U Pedersen-Bjergaard,
- L Potier,
- S Borot,
- B Gaborit,
- A Monier,
- A Pradignac,
- B Verges,
- A Larroumet,
- J-F Thuan,
- A Birkenfeld,
- M Kellerer,
- J Lüdemann,
- M Esser,
- G Kahrmann,
- H-P Kempe,
- T Koch,
- C Axthelm,
- B Paschen,
- L Rose,
- T Schaum,
- J Schulze,
- A Staudenmeyer,
- V Wenzl-Bauer,
- R C W Ma,
- N Thomas,
- V S Reddy,
- P V Rao,
- R Sahay,
- J Singh,
- A Prakash,
- N Tandon,
- T Marwah,
- T Chaudhury,
- S Ghosh,
- A K Kanungo,
- N Mittal,
- J J Jacob,
- M Chadha,
- M Chawla,
- N M Bhagwat,
- S M Jain,
- N K Thulaseedharan,
- G Girithara,
- A Desai,
- S K Sharma,
- S Murthy,
- B K Sethi,
- Y Kadam,
- J Kesavadev,
- B Daxini,
- R Chawla,
- U A Gopalakrishnan,
- M P Baruah,
- S P Reddy,
- K M Suryanarayana,
- K P Singh,
- B Saboo,
- G Aharon-Hananel,
- I Hochberg,
- Y Sofer,
- A Tirosh,
- I Shimon,
- V Vishlitzky,
- A Bashkin,
- A Tsur,
- M Shechter,
- F Andreozzi,
- E Setola,
- A Consoli,
- R Lupoli,
- S Genovese,
- M Maranghi,
- D Lauro,
- R Citarrella,
- G P Fadini,
- G Murdolo,
- A Di Carlo,
- F Giorgino,
- S Buscemi,
- K Hanaoka,
- T Osonoi,
- H Ohashi,
- H Ezaki,
- H Yuki,
- A Kiyosue,
- Y Hata,
- M Sugawara,
- H Domae,
- H Iwata,
- Y Nishida,
- M Igarashi,
- S Fujino,
- A Oiwa,
- F Oh,
- A Sueyoshi,
- T Murakami,
- M Tanaka,
- A Idogaki,
- H Onaka,
- I Mizote,
- M Doi,
- O Ebisui,
- M Tanabe,
- M Natsuaki,
- H Jinnouchi,
- S Nakamura,
- W M I Wan Mohamed,
- N Yahaya,
- J Ratnasingam,
- T K Ong,
- M Mohamad,
- N S Yusoff Azmi Merican,
- R Abdul Ghani,
- N L Adam,
- T L Fam,
- F H S Tan,
- E C Morales Villegas,
- G Gonzalez-Galvez,
- D Espinoza Peralta,
- C E Medina Pech,
- M Arechavaleta-Granell,
- A C García Ulloa,
- H A Laviada Molina,
- R G Banda Elizondo,
- J Á Garza Ruiz,
- E A García Cantú,
- T van Bemmel,
- H W de Valk,
- A Kooy,
- L Lieverse,
- S A N T Landewe-Cleuren,
- K Hoogenberg,
- D van Raalte,
- M Jebbink,
- C Oldenburg-Ligtenberg,
- E Abbink-Zandbergen,
- B Mihai,
- C Crisan,
- I Filip,
- M M Busegeanu,
- G Roman,
- A C Mot,
- A Nicoara,
- V Anghel,
- N N Pletea,
- M Suciu,
- D Strajer,
- S Cernea,
- A Zilov,
- Z Kobalava,
- L A Ruyatkina,
- L A Suplotova,
- M Y Sergeeva-Kondrachenko,
- M E Yanovskaya,
- L Kargina,
- A Ignatyeva,
- K Astamirova,
- A Zalevskaya,
- O Zagrebelnaya,
- E V Frolova,
- A B Peskov,
- O Mishchenko,
- O Otroshchenko,
- L Gaysina,
- O Y Shabelnikova,
- T V Saprina,
- T A Lysenko,
- M Kunitsyna,
- S T Zyangirova,
- N Lalic,
- K Lalic,
- T Beljic Zivkovic,
- S Kikovic,
- A Djukic,
- M Pesic,
- D Dimic,
- E Stokic,
- M Mitrovic,
- S Polovina,
- M Djordjevic,
- D Sosovec,
- D Pella,
- V Donicova,
- S Hanackova Prasekova,
- D Koleny,
- J Culak,
- K Cerna,
- V Hundza,
- J Gmitrov,
- J Lacka,
- R Plasil,
- A Amod,
- H B Bacus,
- Q E Bhorat,
- P Joshi,
- D R Lakha,
- V Makan,
- N Ntusi,
- T Padayachee,
- M E Seeber,
- D Pillay,
- M Joshi,
- L Mayet,
- J Lee,
- S G Kim,
- K W Min,
- E S Kang,
- W J Lee,
- S H Choi,
- C B Lee,
- A López Suárez,
- M Á García Ordóñez,
- A García Quintana,
- P Mazón Ramos,
- S Cigarrán,
- C Barrios,
- A Soto González,
- E Jodar,
- J Delgado Lista,
- C Morales Portillo,
- C Montalbán Carrasco,
- J J Gorgojo Martínez,
- F Tinahones,
- S-T Tu,
- C-N Huang,
- S-T Chen,
- P Buranasupkajorn,
- A Sriwijitkamol,
- S Buranapin,
- A Suwanagool,
- P Tantiwong,
- A Boonyavarakul,
- S Benjachareonwong,
- R Leelawattana,
- P Vathesatogkit,
- C Deerochanawong,
- Y A Sonmez,
- A Oguz,
- O Tabak,
- M Kocak,
- B Sariakcali,
- F Bayram,
- M Guclu,
- E Gurkan,
- N Kebapci,
- A Comlekci,
- F Acibucu,
- S Ahbab,
- H Bilen,
- B Mankovskyy,
- A Urbanovych,
- P Kuskalo,
- I Bondarets,
- O Petrosyan,
- N Pashkovska,
- O Oleksyk,
- I Kaydashev,
- K Maliar,
- G Myshanych,
- S C Bain,
- D Black,
- P Johnston,
- C Dang,
- K Dhatariya,
- P English,
- B Field,
- P Grimmer,
- A Gunstone,
- S Ray,
- D Tatovic,
- A Kernohan,
- R Lindsay,
- J A Mcknight,
- A Park,
- D Patel,
- S Philip,
- H Randeva,
- T Sathyapalan,
- W Turner,
- N Wyatt,
- D C Allison,
- V Awasty,
- E Ayele,
- C Bajaj,
- M J Budoff,
- R Busch,
- J B Buse,
- L Casaubon,
- P A Austin,
- S S Chaidarun,
- R H Chochinov,
- J W Chu,
- N Y Daboul,
- A H Dang,
- C V Desouza,
- B G Everhart,
- J Arambasick,
- R I Fink,
- D Fitz-Patrick,
- C M Fogarty,
- M P Gilbert,
- D M Johnson,
- S S Krishnasamy,
- W S Lane,
- S N Nakhle,
- D Levenson,
- P O'Donnell,
- D Weiss,
- J A Risser,
- C Wierum,
- K Sivalingam,
- D Gupta,
- A Philis-Tsimikas,
- R E Pratley,
- L Mirza,
- B Snyder,
- N Rasouli,
- J Porter,
- G N Ledesma,
- T Powell,
- I J Tandron,
- I Lingvay,
- J C H Reed Iii,
- M B Patel,
- D Lovre,
- T Chaicha-Brom,
- C Jantzi,
- D Brautigam,
- S Bao,
- C N Mbogua,
- L R Zemel,
- S Hasan,
- J Rosenstock,
- H Tran,
- J Poremba,
- C Baker,
- K Prier,
- S Chilka,
- J M Agaiby,
- J Condit,
- D C Eagerton,
- D Huffman,
- G M Cornett,
- H Traylor,
- C Brinson,
- H E Bays,
- T Jerkins,
- P R Nicol,
- I A Siddiqui,
- M Hewitt,
- A O Odugbesan,
- M J Lillestol,
- J R Thrasher,
- W H Gandy,
- N Pant,
- S Nagelberg,
- K Cannon,
- M W Anderson,
- A Bhargava,
- A Doshi,
- M F Jardula,
- M Montero,
- R S Purighalla,
- M L Warren,
- K Harris,
- R A Jackson,
- A S Khaira,
- L Gonzalez-Orozco,
- P J Gagianas,
- K Pantalone,
- A V Murray,
- Darren K McGuire,
- John B Buse,
- John Deanfield,
- Johannes F E Mann,
- Neil Poulter,
- Nikolaus Marx,
- Rodica Pop-Busui,
- Scott Emerson,
- Sharon L Mulvagh,
- Silvio E Inzucchi,
- Kirstine Brown-Frandsen,
- G Kees Hovingh,
- Mads D Engelmann,
- Peter Billeskov Schelde,
- Mads Frederik Rasmussen,
- Stephen C Bain,
- Matthew A Cavender,
- Pardeep Jhund Singh,
- Alberto Lorenzatti,
- Thomas Pieber,
- Chantal Mathieu,
- José Francisco Kerr Saraiva,
- Rosangela Rea,
- Harpreet Bajaj,
- Kim Connelly,
- Linong Ji,
- Robinson Sanchez Garcia,
- Silvija Canecki-Varžić,
- Martin Haluzik,
- Søren Gregersen,
- Monika Kellerer,
- Andreas Birkenfeld,
- Francis Chun Chung Chow,
- V Mohan,
- Tamil Nadu,
- Michael Shechter,
- Agostino Consoli,
- Hirotaka Watada,
- Rohana Abdul Ghani,
- Rosario Arechavaleta Granell,
- Thomas van Bemmel,
- Gabriela Roman,
- Alexey Zilov,
- Zhanna Kobalava,
- Nebojsa Lalic,
- Katarina Cerna,
- Aslam Amod,
- Sin Gon Kim,
- Juan José Gorgojo Martínez,
- Pilar Mazón Ramos,
- Shih-Te Tu,
- Chaicharn Deerochanawong,
- Aytekin Oguz,
- Boris Mankovskyy,
- Cyrus DeSouza,
- Dale Allison,
- James A de Lemos,
- Jeffrey L Saver,
- Deborah J Wexler,
- Linda Fried,
- Jürgen Floege,
- Shaun Goodman,
- Frederick L Ferris,
- Daniel L Gillen,
- Michelle Nuño,
- Matthew T Roe,
- Stephen Wiviott,
- Gregory Ducrocq,
- Thomas Povsic,
- Fatima Rodriguez,
- Rajendra Mehta,
- David Kong,
- Christopher Kontos,
- Lawrence Phillips,
- Sergio Leonardi,
- Kyra J Becker,
- J Dedrick Jordan,
- Gene Sung,
- Keith Dombrowski,
- Deborah Fisher,
- Ziad Gellad,
- Julius Wilder,
- David Leiman,
- Jamie Dwyer,
- John Middleton,
- Kausik Umanath,
- Tara Chang,
- Matthew J Diamond.
Abstract
BACKGROUND
The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the cardiovascular efficacy of oral semaglutide in persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both is needed.
METHODS
In this double-blind, placebo-controlled, event-driven, superiority trial, we randomly assigned participants who were 50 years of age or older, had type 2 diabetes with a glycated hemoglobin level of 6.5 to 10.0%, and had known atherosclerotic cardiovascular disease, chronic kidney disease, or both to receive either once-daily oral semaglutide (maximal dose, 14 mg) or placebo, in addition to standard care. The primary outcome was major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke), assessed in a time-to-first-event analysis. The confirmatory secondary outcomes included major kidney disease events (a five-point composite outcome).
RESULTS
Among the 9650 participants who had undergone randomization, the mean (±SD) follow-up was 47.5±10.9 months, and the median follow-up was 49.5 months. A primary-outcome event occurred in 579 of the 4825 participants (12.0%; incidence, 3.1 events per 100 person-years) in the oral semaglutide group, as compared with 668 of the 4825 participants (13.8%; incidence, 3.7 events per 100 person-years) in the placebo group (hazard ratio, 0.86; 95% confidence interval, 0.77 to 0.96; P = 0.006). The results for the confirmatory secondary outcomes did not differ significantly between the two groups. The incidence of serious adverse events was 47.9% in the oral semaglutide group and 50.3% in the placebo group; the incidence of gastrointestinal disorders was 5.0% and 4.4%, respectively.
CONCLUSIONS
Among persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, the use of oral semaglutide was associated with a significantly lower risk of major adverse cardiovascular events than placebo, without an increase in the incidence of serious adverse events. (Funded by Novo Nordisk; SOUL ClinicalTrials.gov number, NCT03914326.).
References
Cited by 414 citations (total)
Journal Article Review
The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions.
Electronic publication date July 29, 2025
Areesha Moiz [...] Mark J Eisenberg et al.
Journal Article Review
Obesity-Related Kidney Disease: A Growing Threat to Renal Health.
Electronic publication date July 30, 2025
Juan León-Román [...] María José Soler et al.
Obesity represents a serious and growing disease worldwide. The pathophysiological changes secondary to chronic inflammation lead to the development of...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
Substances
- •
- •
- •
Copyright
Copyright © 2025 Massachusetts Medical Society.